Dr. James Cleary explains how the researchers at Dana-Farber are looking to make PARP inhibitors even more effective for pancreatic cancer patients.
When Scott Nelson was diagnosed with pancreatic cancer, oldest brother Steve began regular screening, which lead to his early diagnosis.
With stage IV pancreatic cancer, Rick Baker got molecular profiling which helped direct his different treatments, including clinical trials.
A study by Dr. Gloria Petersen’s research team has led to an official recommendation that all pancreatic cancer patients get genetic testing.
Miriam Hermosa decided to take advantage of her relatively good health and try pancreatic cancer treatment with FOLFIRINOX to get more time with her family.
Dr. Allyson Ocean leads an overview of the new treatments and protocol from 2018 as well as what are the next steps in treatment for 2019.
Genetics impact your treatment for pancreatic cancer. Dr. Sapna Syngal discusses the recommendation of genetic testing for all pancreatic cancer patients.
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.
When Florida resident Doron Broman was diagnosed with stage IV pancreatic cancer, his decision to get treated in Boston gave him access a PARP inhibitor for maintenance.
Marisa Harris was given a devastating diagnosis of stage IV pancreatic cancer. She tapped the power within herself, as well as chemotherapy, to become a long-term survivor.
Professor Gloria Peterson of the Mayo Clinic is working on tumor genetics to help make early detection of pancreatic cancer a reality.